A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation.
Principal Investigator
Dott.ssa Chiara Lazzari
Contact Information for Access
Phase
FASE III
Status
ATTIVO
Objective of the study
To compare the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab alone as first-line treatment for NSCLC with a KRAS G12C mutation and a TPS of 50% or greater.
Pathologies
Lung Cancer
Medication
Adagrasib (KRAS G12C inhibitor)
Pembrolizumab (PD-L1 antagonist—immunotherapy)
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with advanced and/or metastatic non-small cell lung cancer (NSCLC) who have a KRAS G12C mutation.
Back to search page